A5100753627- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
- BRCA gene mutations in cancer
- Immunotherapy and Immune Responses
- Vascular Tumors and Angiosarcomas
- Radiopharmaceutical Chemistry and Applications
- Cancer Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Monoclonal and Polyclonal Antibodies Research
- Multiple and Secondary Primary Cancers
- Lung Cancer Treatments and Mutations
- Global Cancer Incidence and Screening
- Urological Disorders and Treatments
- Food, Nutrition, and Cultural Practices
- PARP inhibition in cancer therapy
- Adrenal Hormones and Disorders
- Effects and risks of endocrine disrupting chemicals
- Women's cancer prevention and management
- Psoriasis: Treatment and Pathogenesis
- Pituitary Gland Disorders and Treatments
Hospital Universitario Ramón y Cajal
2016-2025
Universidad de Alcalá
2024
Instituto Cajal
2023-2024
Instituto Ramón y Cajal de Investigación Sanitaria
2022-2023
The University of Texas Health Science Center at San Antonio
2019-2022
The University of Texas Health Science Center at Houston
2002-2020
Istituto Oncologico Veneto
2018
National Taiwan University Hospital
2018
Eli Lilly (Spain)
2018
Orlando Health
2018
Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy not yet been evaluated active brain metastases (BMs). DEBBRAH aims to assess T-DXd or HER2-low ABC and central nervous system involvement.This ongoing, five-cohort, phase II study (NCT04420598) enrolled stable, untreated, progressing BMs, and/or leptomeningeal carcinomatosis. Here, we report findings from non-progressing BMs after local...
IntroductionPatients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding vaccines immunogenicity in this population is crucial for adequately planning programs. The ONCOVac study aimed to comprehensively assess the mRNA-1273 vaccine terms humoral cellular response.MethodsWe conducted a prospective, single-center including patients solid tumours treated cyclin-dependent kinases 4 6 inhibitors (CDK4/6i), immunotherapy (IT) or...
Abstract Background: Leptomeningeal carcinomatosis (LMC) occurs in approximately 5-15% of patients (pts) with advanced breast cancer (ABC) and is associated poor survival a significant reduction quality life. The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has shown remarkable intracranial extracranial activity, leading to its widespread clinical use. DEBBRAH evaluating the efficacy safety T-DXd pts HER2[+] HER2-low ABC history brain metastases (BM) and/or LMC. Here, we report...
Abstract Background: Abemaciclib is a selective oral inhibitor of CDK4 and CDK6. Dosed on continuous schedule, abemaciclib showed evidence antitumor clinical activity in patients (pts) with metastatic BC monotherapy or combination non-steroidal aromatase (NSAI) fulvestrant. NeoMONARCH (NCT02441946) Phase 2 trial women stage I-IIIB, HR+/HER2- evaluating neoadjuvant treatment + anastrozole, ANZ. As previously reported, met its primary endpoint showing abemaciclib, alone ANZ, significantly...
Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma situ (DCIS) of the breast and associated with poorly differentiated tumors adverse prognosis features. This study aimed to determine molecular effects HER2 inhibitor lapatinib patients positive DCIS. Patients DCIS received 1,500 mg daily for four consecutive weeks prior surgical resection. Magnetic resonance imaging (MRI) was used changes tumor volume. The on signaling (PI3K/AKT RAS/MAPK pathways),...
To evaluate the efficacy and safety of combination olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) germinal BRCA mutations (gBRCAm).
The overall aim of this study was to describe trends in participation rates and detection lesions a colorectal cancer (CRC) screening programme, during three rounds, using faecal immunochemical test (FIT). National registers were used collect data on invitations for CRC the Basque Country (Spain) from 2009 2014. Information about participation, age, gender each round collected. A total 961.533 individuals included analysis; respectively, 584.950, 298.143 78.440 first, second third rounds....
Abstract The DEBBRAH study (NCT04420598) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with HER2-positive HER2-low ABC brain metastases (BM) and/or LMC. Forty-one aged ≥18 years were enrolled 5 cohorts: (1) non-progressing BM after radiotherapy surgery (n=8); (2) or asymptomatic untreated (n=10); (3) progressing local treatment (n=9); (4) (n=7); (5) pathologically confirmed LMC (n=7). Patients received 5.4 mg/kg T-DXd...
Few data are available about the immune response to mRNA SARS-CoV-2 vaccines in patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). We conducted a prospective, single-center study of treated CDK4/6i who received mRNA-1273 vaccination, as well comparative group healthcare workers. The primary endpoint was compare rate and magnitude humoral T-cell after full vaccination. A better neutralizing antibody anti-S IgG level observed vaccination subgroup women...
Abstract Background: Cyclin-dependent kinases 4 and 6 inhibitors in combination with endocrine therapy frequently lead to a complete cell-cycle arrest (CCCA) luminal EBC. However, the rates of pathological response (pCR) or Residual Cancer Burden (RCB) 0-I are modest. The effect this treatment terms molecular downstaging as assessed by genomic signature more refined than Ki67 remains undetermined. We aimed assess biological clinical activity letrozole plus palbociclib neoadjuvant...
1061 Background: CDKi + ET combinations have demonstrated efficacy in improving progression-free survival (PFS) and overall (ribociclib) HR+/HER2- aBC the first-line setting. Intrinsic subtypes (IS) are prognostic predict benefit from ET. The multiparametric PAM50MET score has value prior to widespread use of patients. Here we developed a new based on PAM50 assay metastatic baseline biopsies within CDK-PREDICT (SOLTI-1801) study Hospital Clinic de Barcelona (HCB) cohort. Methods: RNA FFPE...
Abstract B cells frequently infiltrate breast cancer (BCa) tumors, but their roles are inadequately understood. As shown by our analyses of the TCGA datasets and human BCa arrays, tumoral expression cell hallmark factors (e.g., CD20 PAX5) coincides with those two subunits pleiotropic cytokine IL-27, EBI3 IL-27p28, whose is associated poor prognosis in patients. In syngeneic mouse models, promote progression do so producing not IL-35 (IL-12/EBI3 heterodimer). Upon treatment recombinant IL-27...
Background: Educational attainment and health are mutually reinforcing outcomes. Good supports children in the achievement of academic milestones, such as grade-level reading, is associated with higher socio-economic status, longer life expectancy, lower lifelong chronic disease. Improving outcomes increasing potential for high educational necessary reducing disparities, improving population health, morbidity. Early childhood settings present opportunities to address health.
Abstract Background: The PI3K/AKT/mTOR signaling pathway plays a key role for the growth and survival of breast cancer cells aberrations such as phosphatidylinositol-3-kinase (PI3KCA) mutations are common. BKM120 is an oral pan-class I PI3KCA inhibitor. aim this study was to evaluate neoadjuvant treatment with in mutated early order assess effect PI3K/Akt/mTOR signalling pathway. Methods: Patients (pts) previously untreated invasive, non-metastatic histologically confirmed cancer, tumor size...